A Novel NF2 Mutation Associated with Neurofibromatosis Type 2 Causes Aberrant Splicing and Phase Separation
Zexiao Jia,Shuxu Yang,Mengyao Li,Zhaoying Lei,Xue Ding,Mingjie Fan,Dixian Wang,Dajiang Xie,Hui Zhou,Yue Qiu,Qianqian zhuang,Dan Li,Wei Yang,Xuchen Qi,Xiaohui Cang,Jing-Wei Zhao,Wenqi Wang,Aifu Lin,Qingfeng Yan
DOI: https://doi.org/10.2139/ssrn.4066027
2022-01-01
SSRN Electronic Journal
Abstract:Neurofibromatosis type 2 is an autosomal dominant multiple neoplasia syndrome. It affects one in 25,000 individuals in the general population. Neurofibromatosis type 2 is usually caused by mutations in the neurofibromin 2 (NF2) gene, which encodes a tumor suppressor and initiates the Hippo pathway. However, the mechanism by which NF2 recruits LATS to the plasma membrane and functions in Hippo pathway is not yet fully understood. Here we identified a novel c.770-784del mutation of the NF2 gene from a neurofibromatosis type 2 family. The deleted sequence encoded five amino acids (Pro-Trp-Asn-Glu-Ile) from the 257 to 261 positions of the NF2 protein. MD simulations showed that the variant significantly changed the structure of the F3 module of the NF2-FERM domain. Functional assays indicated that this deletion impaired NF2 localization to the plasma membrane, in which the hydrophobic Trp258 residue is crucial. The NF2 c.770-784del variant formed the liquid-liquid phase separation in the cytoplasm with LATS, reduced phosphorylation of LATS and inactivated the Hippo pathway, thereby promoting the elevated proliferation and tumorigenesis of meningeal cells. Furthermore, this NF2 c.770-784del caused a skipping of exon 8 and reduced the protein level of NF2, which also inhibit Hippo pathway. We identified the molecular mechanism by which NF2 regulated the Hippo pathway, and provided new insight into the pathogenesis of neurofibromatosis type 2 that occurs via NF2 mutation.